VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Weymouth Street Hospital 42-46 Weymouth St, Marylebone,, UK
+44 20 7935 1200
